Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Short-term Investments (2023 - 2026)

Orthofix Medical has reported Short-term Investments over the past 6 years, most recently at $592000.0 for Q1 2026.

  • For the quarter ending Q1 2026, Short-term Investments fell 76.32% year-over-year to $592000.0, compared with a TTM value of $592000.0 through Mar 2026, down 76.32%, and an annual FY2025 reading of $3.1 million, up 23.6% over the prior year.
  • Short-term Investments came in at $592000.0 for Q1 2026, down from $3.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $4.6 million in Q4 2023 to a low of $592000.0 in Q1 2026.
  • Median Short-term Investments over the past 4 years was $2.5 million (2024), compared with a mean of $2.7 million.
  • The sharpest move saw Short-term Investments grew 23.6% in 2025, then crashed 76.32% in 2026.
  • Over 4 years, Short-term Investments stood at $4.6 million in 2023, then crashed by 46.24% to $2.5 million in 2024, then grew by 23.6% to $3.1 million in 2025, then tumbled by 80.84% to $592000.0 in 2026.
  • Per Business Quant, the three most recent readings for OFIX's Short-term Investments are $592000.0 (Q1 2026), $3.1 million (Q4 2025), and $3.1 million (Q3 2025).